

References

X-5026

1. Riberich R. FDA-Approved PET Radiopharmaceuticals. <http://www.radiopharmaceuticals.info/pet-radiopharmaceuticals.html>. Accessed July 19, 2022.
2. Jadvar H. Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer. *Radiology*. Sep 2022; 304(3): 609-610. PMID 35608452
3. Zhang H, Xing W, Kang Q, et al. Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis. *Tumour Biol*. May 2015; 36(5): 3209-14. PMID 25809703
4. van der Pol CB, Sahni VA, Eberhardt SC, et al. ACR Appropriateness Criteria (R) Pretreatment Staging of Muscle-Invasive Bladder Cancer. *J Am Coll Radiol*. May 2018; 15(5S): S150-S159. PMID 29724418
5. Allen BC, Oto A, Akin O, et al. ACR Appropriateness Criteria(R) Post-Treatment Surveillance of Bladder Cancer: 2021 Update. *J Am Coll Radiol*. May 2021; 18(5S): S126-S138. PMID 33958107
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed July 20, 2022.
7. Zhang Q, Xi Y, Li D, et al. The utility of 18 F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis. *J Orthop Surg Res*. Jun 22 2020; 15(1): 229. PMID 32571371
8. Liu F, Zhang Q, Zhu D, et al. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)*. Sep 2015; 94(36): e1462. PMID 26356700
9. Treglia G, Salsano M, Stefanelli A, et al. Diagnostic accuracy of F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. *Skeletal Radiol*. Mar 2012; 41(3): 249-56. PMID 22072239
10. Bestic JM, Wessell DE, Beaman FD, et al. ACR Appropriateness Criteria(R) Primary Bone Tumors. *J Am Coll Radiol*. May 2020; 17(5S): S226-S238. PMID 32370967
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed July 21, 2022.

12. Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. *Neuro Oncol.* Mar 2016; 18(3): 426-34. PMID 26243791
13. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. *J Nucl Med.* Feb 2012; 53(2): 207-14. PMID 22302961
14. Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors. *AJNR Am J Neuroradiol.* Jun 2014; 35(6): 1058-65. PMID 24029389
15. Deng SM, Zhang B, Wu YW, et al. Detection of glioma recurrence by C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. *Nucl Med Commun.* Aug 2013; 34(8): 758-66. PMID 23670103
16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed July 22, 2022.
17. Liang X, Yu J, Wen B, et al. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. *Clin Radiol.* Apr 2017; 72(4): 295-301. PMID 28139203
18. Caldarella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. *Clin Breast Cancer.* Aug 2014; 14(4): 241-8. PMID 24472718
19. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. *Med Sci Monit.* Mar 2007; 13(3): RA37-46. PMID 17325645
20. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography in Breast Cancer. *Technol Eval Cent Assess.* 2001;16(5).
21. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Evaluating Breast Cancer. *Technol Eval Cent Assess.* 2003;18(14).
22. Han S, Choi JY. Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis. *Clin Nucl Med.* Apr 01 2021; 46(4): 271-282. PMID 33651022
23. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. *Surg Oncol.* Jun 2013; 22(2): 139-43. PMID 23566435

24. Rong J, Wang S, Ding Q, et al. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. Jun 2013; 22(2): 86-91. PMID 23726506
25. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. *Breast Cancer Res Treat*. Mar 2005; 90(2): 105-12. PMID 15803356
26. Xiao Y, Wang L, Jiang X, et al. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. *Nucl Med Commun*. Nov 2016; 37(11): 1180-8. PMID 27428888
27. Liu Q, Wang C, Li P, et al. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. *Biomed Res Int*. 2016; 2016: 3746232. PMID 26981529
28. Sheikhabaei S, Trahan TJ, Xiao J, et al. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. *Oncologist*. Aug 2016; 21(8): 931-9. PMID 27401897
29. Li H, Yao L, Jin P, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. *Breast*. Aug 2018; 40: 106-115. PMID 29758503
30. Cheng X, Li Y, Liu B, et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. *Acta Radiol*. Jul 2012; 53(6): 615-27. PMID 22734080
31. Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. *Breast Cancer Res Treat*. Jan 2012; 131(2): 357-69. PMID 21960111
32. Moy L, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria (R) Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. *J Am Coll Radiol*. May 2017; 14(5S): S282-S292. PMID 28473085
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 24, 2022.
34. Chu Y, Zheng A, Wang F, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. *Nucl Med Commun*. Feb 2014; 35(2): 144-50. PMID 24177043
35. Ospina MB, Horton J, Seida J, et al. Technology Assessment Report : Positron emission tomography for nine cancers (bladder, brain, cervical, kidney,

- ovarian, pancreatic, prostate, small cell lung, testicular). Rockville, MD: Agency for Healthcare Research and Quality; 2008.
36. Yen TC, See LC, Chang TC, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. *J Nucl Med*. Oct 2004; 45(10): 1632-9. PMID 15471826
 37. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. *J Natl Compr Canc Netw*. Jun 2009; 7 Suppl 2: S1-26. PMID 19555588
 38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed July 23, 2022.
 39. Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. *Br J Radiol*. Dec 2017; 90(1080): 20170370. PMID 28972796
 40. Jones M, Hruby G, Solomon M, et al. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. *Ann Surg Oncol*. Oct 2015; 22(11): 3574-81. PMID 25652048
 41. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Colorectal Cancer. *Technol Eval Cent Assess*. 1999;14(25).
 42. Albertsson P, Alverbratt C, Liljegren A, et al. Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. Jun 2018; 126: 6-12. PMID 29759568
 43. Ye Y, Liu T, Lu L, et al. Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients. *Int J Clin Exp Med*. 2015; 8(11): 21773-85. PMID 26885142
 44. Li C, Lan X, Yuan H, et al. 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. *Ann Nucl Med*. Jun 2014; 28(5): 436-46. PMID 24623152
 45. Maffione AM, Chondrogiannis S, Capirci C, et al. Early prediction of response by F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. *Eur J Surg Oncol*. Oct 2014; 40(10): 1186-94. PMID 25060221
 46. Memon S, Lynch AC, Akhurst T, et al. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. *Ann Surg Oncol*. Oct 2014; 21(11): 3598-607. PMID 24802909
 47. Gwynne S, Mukherjee S, Webster R, et al. Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review. *Clin Oncol (R Coll Radiol)*. Feb 2012; 24(1): 52-63. PMID 22035634

48. Rymer B, Curtis NJ, Siddiqui MR, et al. FDG PET/CT Can Assess the Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy: Evidence From Meta-analysis and Systematic Review. *Clin Nucl Med*. May 2016; 41(5): 371-5. PMID 26914561
49. Yu T, Meng N, Chi D, et al. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies. *Cell Biochem Biophys*. Jun 2015; 72(2): 443-51. PMID 25737131
50. Maffione AM, Marzola MC, Capirci C, et al. Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. *AJR Am J Roentgenol*. Jun 2015; 204(6): 1261-8. PMID 26001237
51. Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. *Int J Colorectal Dis*. Aug 2013; 28(8): 1039-47. PMID 23407908
52. Sobhani I, Itti E, Luciani A, et al. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. *Ann Oncol*. Apr 01 2018; 29(4): 931-937. PMID 29365058
53. Fowler KJ, Kaur H, Cash BD, et al. ACR Appropriateness Criteria (R) Pretreatment Staging of Colorectal Cancer. *J Am Coll Radiol*. May 2017; 14(5S): S234-S244. PMID 28473079
54. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed July 25, 2022.
55. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed August 13, 2022.
56. Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. *J Nucl Med*. Jun 2016; 57(6): 879-85. PMID 26823564
57. Reinhold C, Ueno Y, Akin EA, et al. ACR Appropriateness Criteria(R) Pretreatment Evaluation and Follow-Up of Endometrial Cancer. *J Am Coll Radiol*. Nov 2020; 17(11S): S472-S486. PMID 33153558
58. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed August 20, 2022.

59. Kroese TE, Goense L, van Hillegersberg R, et al. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. *Dis Esophagus*. Dec 01 2018; 31(12). PMID 29917073
60. Cong L, Wang S, Gao T, et al. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis. *Jpn J Clin Oncol*. Dec 2016; 46(12): 1118-1126. PMID 27702836
61. Goense L, van Rossum PS, Reitsma JB, et al. Diagnostic Performance of F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis. *J Nucl Med*. Jul 2015; 56(7): 995-1002. PMID 25952733
62. Shi W, Wang W, Wang J, et al. Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. *Surg Oncol*. Jun 2013; 22(2): 112-6. PMID 23478047
63. American College of Radiology. ACR Appropriateness Criteria: Staging and Follow-up of Esophageal Cancer. 2022. Accessed August 1, 2022.
64. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Cancer. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed August 3, 2022.
65. Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. *Ann Nucl Med*. Apr 2016; 30(3): 179-87. PMID 26830546
66. Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. *Surg Oncol*. Sep 2013; 22(3): 162-6. PMID 23747134
67. Wu LM, Hu JN, Hua J, et al. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. *J Gastroenterol Hepatol*. Mar 2012; 27(3): 472-80. PMID 21916986
68. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed August 4, 2022.
69. Chen WS, Li JJ, Hong L, et al. Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies. *Am J Transl Res*. 2016; 8(11): 4532-4547. PMID 27904660

70. Wei J, Pei S, Zhu X. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis. *Oral Oncol.* Jan 2016; 52: 11-7. PMID 26547126
71. Cheung PK, Chin RY, Eslick GD. Detecting Residual/Recurrent Head Neck Squamous Cell Carcinomas Using PET or PET/CT: Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg.* Mar 2016; 154(3): 421-32. PMID 26715675
72. Sheikhabahaei S, Taghipour M, Ahmad R, et al. Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. *AJR Am J Roentgenol.* Sep 2015; 205(3): 629-39. PMID 26295652
73. Sheikhabahaei S, Ahn SJ, Moriarty E, et al. Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. *AJR Am J Roentgenol.* Nov 2015; 205(5): 1102-13. PMID 26496559
74. Rohde M, Dyrvig AK, Johansen J, et al. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Eur J Cancer.* Sep 2014; 50(13): 2271-9. PMID 25011659
75. Yi X, Fan M, Liu Y, et al. 18 FDG PET and PET-CT for the detection of bone metastases in patients with head and neck cancer. A meta-analysis. *J Med Imaging Radiat Oncol.* Dec 2013; 57(6): 674-9. PMID 24283555
76. Gao S, Li S, Yang X, et al. 18FDG PET-CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. *Oral Oncol.* Mar 2014; 50(3): 163-7. PMID 24368204
77. Helsen N, Van den Wyngaert T, Carp L, et al. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. *Eur J Nucl Med Mol Imaging.* Jun 2018; 45(6): 1063-1071. PMID 29478080
78. Li Q, Zhang J, Cheng W, et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. *Medicine (Baltimore).* Sep 2017; 96(37): e8084. PMID 28906411
79. Lin J, Xie G, Liao G, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. *Oncotarget.* May 16 2017; 8(20): 33884-33896. PMID 27980228
80. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Head and Neck Cancer. *Technol Eval Cent Assess.* 2000;15(4).

81. Zhu Y, McLaren O, Hardman J, et al. Systematic review and meta-analysis of the diagnostic effectiveness of PET-CT versus MRI in the post-treatment surveillance of head and neck squamous cell carcinoma. *J Laryngol Otol.* Jan 28 2022; 1-31. PMID 35086577
82. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed August 5, 2022.
83. Barger RL, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. *Acad Radiol.* Feb 2012; 19(2): 153-8. PMID 22104289
84. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Non-CNS Cancers. *Technol Eval Cent Assess.* 1997;12(3).
85. Brea TP, Ravina AR, Villamor JMC, et al. Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review. *Arch Bronconeumol (Engl Ed).* Jan 2019; 55(1): 9-16. PMID 29803524
86. Ruilong Z, Daohai X, Li G, et al. Diagnostic value of 18F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. *Nucl Med Commun.* Jan 2017; 38(1): 67-75. PMID 27741214
87. He YQ, Gong HL, Deng YF, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. *Acta Radiol.* Apr 2014; 55(3): 309-17. PMID 24081215
88. Seol HY, Kim YS, Kim SJ. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer. *Oncology.* 2021; 99(2): 96-104. PMID 32980838
89. Li Y, Jin G, Su D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. *Oncotarget.* May 30 2017; 8(22): 35743-35749. PMID 28415747
90. Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. *Surg Oncol.* Sep 2013; 22(3): 151-5. PMID 23664848
91. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* May 2013; 143(5 Suppl): e211S-e250S. PMID 23649440

92. de Groot PM, Chung JH, Ackman JB, et al. ACR Appropriateness Criteria (R) Noninvasive Clinical Staging of Primary Lung Cancer. *J Am Coll Radiol*. May 2019; 16(5S): S184-S195. PMID 31054745
93. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 7, 2022.
94. Lu YY, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. *Nucl Med Commun*. Jul 2014; 35(7): 697-703. PMID 24694775
95. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. *J Thorac Oncol*. Jun 2012; 7(6): 1015-20. PMID 22534816
96. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed August 14, 2022.
97. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Lymphoma. *Technol Eval Cent Assess*. 1999;14(26).
98. Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. *Ann Oncol*. May 2014; 25(5): 921-7. PMID 24351400
99. Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. Mar 2014; 41(3): 565-74. PMID 24281821
100. Park HY, Suh CH, Huang RY, et al. Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis. *AJR Am J Roentgenol*. May 2021; 216(5): 1172-1182. PMID 32812800
101. Adams HJA, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. *Eur J Radiol*. Nov 2016; 85(11): 1963-1970. PMID 27776647
102. Adams HJ, Nievelstein RA, Kwee TC. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis. *Pediatr Hematol Oncol*. 2015; 32(8): 515-24. PMID 26561044

103. Adams HJ, Kwee TC. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. *Eur J Haematol*. Apr 2017; 98(4): 337-347. PMID 27943422
104. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. *Ann Hematol*. Apr 2016; 95(5): 695-706. PMID 26931115
105. Zhu D, Xu XL, Fang C, et al. Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immunotherapy: a systematic review and meta-analysis. *Int J Clin Exp Med*. 2015; 8(9): 15340-50. PMID 26629023
106. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet*. Dec 23 2017; 390(10114): 2790-2802. PMID 29061295
107. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed August 6, 2022.
108. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed August 28, 2022.
109. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 5.2022. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed July 26, 2022.
110. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed August 12, 2022.
111. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed August 16, 2022.
112. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography in Melanoma. *Technol Eval Cent Assess*. 1999;14(27).

113. Rodriguez Rivera AM, Alabbas H, Ramjaun A, et al. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol*. Mar 2014; 23(1): 11-6. PMID 24556310
114. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed July 29, 2022.
115. Lu YY, Chen JH, Lin WY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. *Clin Nucl Med*. Sep 2012; 37(9): 833-7. PMID 22889770
116. van Lammeren-Venema D, Regelink JC, Riphagen II, et al. F-fluorodeoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. *Cancer*. Apr 15 2012; 118(8): 1971-81. PMID 21887677
117. Han S, Woo S, Kim YI, et al. Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. *Eur Radiol*. Jan 2021; 31(1): 152-162. PMID 32809165
118. Rama S, Suh CH, Kim KW, et al. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis. *AJR Am J Roentgenol*. Apr 2022; 218(4): 602-613. PMID 34704461
119. Mesguich C, Hulin C, Latrabe V, et al. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. *Ann Hematol*. Dec 2020; 99(12): 2869-2880. PMID 32951093
120. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 5.2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed August 1, 2022.
121. Barrio M, Czernin J, Fanti S, et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. *J Nucl Med*. May 2017; 58(5): 756-761. PMID 28082438
122. Deppen SA, Blume J, Bobbey AJ, et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. *J Nucl Med*. Jun 2016; 57(6): 872-8. PMID 26769864
123. Treglia G, Castaldi P, Rindi G, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic

- and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. *Endocrine*. Aug 2012; 42(1): 80-7. PMID 22350660
124. Treglia G, Cocciolillo F, de Waure C, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. *Eur J Nucl Med Mol Imaging*. Jul 2012; 39(7): 1144-53. PMID 22358431
125. Delpassand ES, Ranganathan D, Wagh N, et al. 64 Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial. *J Nucl Med*. Jun 2020; 61(6): 890-896. PMID 31924723
126. Johnbeck CB, Knigge U, Loft A, et al. Head-to-Head Comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. *J Nucl Med*. Mar 2017; 58(3): 451-457. PMID 27660147
127. Xu B, Ma J, Jiang G, et al. Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis. *J Obstet Gynaecol Res*. Feb 2017; 43(2): 378-386. PMID 28150407
128. Limei Z, Yong C, Yan X, et al. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. *Int J Gynecol Cancer*. May 2013; 23(4): 598-607. PMID 23502451
129. Matchar DB, Kulasingam SL, Havrilesky L, et al. *Positron Emission Testing for Six Cancers (Brain, Cervical, Small Cell Lung, Ovarian, Pancreatic and Testicular)*. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
130. Kang SK, Reinhold C, Atri M, et al. ACR Appropriateness Criteria (R) Staging and Follow-Up of Ovarian Cancer. *J Am Coll Radiol*. May 2018; 15(5S): S198-S207. PMID 29724422
131. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma*. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed August 11, 2022.
132. Best LM, Rawji V, Pereira SP, et al. Imaging modalities for characterising focal pancreatic lesions. *Cochrane Database Syst Rev*. Apr 17 2017; 4: CD010213. PMID 28415140
133. Wang L, Dong P, Wang WG, et al. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. *Int J Surg*. Oct 2017; 46: 119-125. PMID 28890410

134. Rijkers AP, Valkema R, Duivenvoorden HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. *Eur J Surg Oncol*. Jul 2014; 40(7): 794-804. PMID 24755095
135. Ghaneh P, Hanson R, Titman A, et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. *Health Technol Assess*. Feb 2018; 22(7): 1-114. PMID 29402376
136. Qayyum A, Tamm EP, Kamel IR, et al. ACR Appropriateness Criteria (R) Staging of Pancreatic Ductal Adenocarcinoma. *J Am Coll Radiol*. Nov 2017; 14(11S): S560-S569. PMID 29101993
137. Lee SW, Kim SJ. Diagnostic Performance of 18F-FDG PET/CT for Lymph Node Staging in Penile Cancer. *Clin Nucl Med*. May 01 2022; 47(5): 402-408. PMID 35143458
138. Jakobsen JK, Frahm Nielsen T, Ipsen P, et al. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. *BJU Int*. Feb 2021; 127(2): 254-262. PMID 33448605
139. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. Accessed August 10, 2022.
140. Liu J, Chen Z, Wang T, et al. Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis. *Cell Physiol Biochem*. 2016; 39(2): 467-80. PMID 27383216
141. Ouyang Q, Duan Z, Lei J, et al. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis. *Tumour Biol*. Mar 2016; 37(3): 2999-3007. PMID 26415734
142. Biscontin G, Romagnolo C, Cottignoli C, et al. 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis. *Diagnostics (Basel)*. Feb 13 2021; 11(2). PMID 33668673
143. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. *Eur J Nucl Med Mol Imaging*. Jan 2016; 43(1): 55-69. PMID 26450693

144. von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. *Nucl Med Commun.* Mar 2014; 35(3): 221-30. PMID 24240194
145. Umbehr MH, Muntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. *Eur Urol.* Jul 2013; 64(1): 106-17. PMID 23628493
146. Mohsen B, Giorgio T, Rasoul ZS, et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. *BJU Int.* Dec 2013; 112(8): 1062-72. PMID 23937453
147. Sandgren K, Westerlinck P, Jonsson JH, et al. Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomy-A Systematic Review. *Eur Urol Focus.* Jul 2019; 5(4): 550-560. PMID 29133278
148. Albisinni S, Aoun F, Marcelis Q, et al. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. *Minerva Urol Nefrol.* Aug 2018; 70(4): 347-360. PMID 29388415
149. Jani AB, Schreibmann E, Goyal S, et al. 18 F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. *Lancet.* May 22 2021; 397(10288): 1895-1904. PMID 33971152
150. Dreyfuss AD, Ahn GS, Barsky AR, et al. 18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis. *Clin Nucl Med.* Mar 01 2021; 46(3): 187-194. PMID 33315672
151. Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. *J Urol.* Feb 2019; 201(2): 322-331. PMID 30179618
152. Akin-Akintayo OO, Jani AB, Odewole O, et al. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. *Clin Nucl Med.* Jan 2017; 42(1): e22-e28. PMID 27749412
153. Treglia G, Ceriani L, Sadeghi R, et al. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. *Clin Chem Lab Med.* May 2014; 52(5): 725-33. PMID 24310773

154. Froemming AT, Verma S, Eberhardt SC, et al. ACR Appropriateness Criteria (R) Post-treatment Follow-up Prostate Cancer. *J Am Coll Radiol*. May 2018; 15(5S): S132-S149. PMID 29724417
155. Lowrance WT, Breau RH, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. *J Urol*. Jan 2021; 205(1): 14-21. PMID 32960679
156. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed July 12, 2022.
157. Jadvar H, Ballas LK, Choyke PL, et al. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. *Journal of Nuclear Medicine*. Apr 1 2020; 61(4): 552-562.
158. Eissa A, Elsherbiny A, Coelho RF, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. *Minerva Urol Nefrol*. Oct 2018; 70(5): 462-478. PMID 29664244
159. Kawada T, Yanagisawa T, Rajwa P, et al. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. Aug 2022; 5(4): 390-400. PMID 35715320
160. Stabile A, Pellegrino A, Mazzone E, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. *Eur Urol Oncol*. Feb 2022; 5(1): 1-17. PMID 34538770
161. Wang X, Wen Q, Zhang H, et al. Head-to-Head Comparison of 68 Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis. *Front Oncol*. 2021; 11: 737989. PMID 34745959
162. Mazrani W, Cook GJR, Bomanji J. Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. *Nucl Med Commun*. Jun 01 2022; 43(6): 631-637. PMID 35438666
163. Pozdnyakov A, Kulanthaivelu R, Bauman G, et al. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of

- prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis.* Apr 19 2022. PMID 35440642
164. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet.* Apr 11 2020; 395(10231): 1208-1216. PMID 32209449
165. Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY). *J Urol.* Jul 2021; 206(1): 52-61. PMID 33634707
166. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic Performance of 18 F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. *Clin Cancer Res.* Jul 01 2021; 27(13): 3674-3682. PMID 33622706
167. Food and Drug Administration. Piflufolastat F 18 (PYLARIFY): Multi-disciplinary Review and Evaluation. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000MultidisciplineR.pdf Accessed July 24, 2022.
168. Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. *JAMA Oncol.* Nov 01 2021; 7(11): 1635-1642. PMID 34529005
169. Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. *JAMA Oncol.* Jun 01 2019; 5(6): 856-863. PMID 30920593
170. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 1.2022. Accessed July 1, 2022.
171. Jadvar H, Calais J, Fanti S, et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. *J Nucl Med.* Jan 2022; 63(1): 59-68. PMID 34593595
172. American Society of Clinical Oncology. Choosing Wisely: Ten Things Physicians and Patients Should Questions. July 26, 2021. Accessed August 25, 2022.
173. Eastham JA, Aufferberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. *J Urol.* Jul 2022; 208(1): 10-18. PMID 35536144

174. Ma H, Shen G, Liu B, et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. *Nucl Med Commun.* Feb 2017; 38(2): 156-163. PMID 27824726
175. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed July 30, 2022.
176. Treglia G, Mirk P, Stefanelli A, et al. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. *Clin Imaging.* May-Jun 2012; 36(3): 167-75. PMID 22542374
177. Ioannidis JPA, Lau J. FDG-PET for the Diagnosis and Management of Soft Tissue Sarcoma (Contract No. 290- 97-0019). Rockville, MD: Agency for Healthcare Research and Quality; 2002.
178. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed August 15, 2022.
179. Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. *Eur J Radiol.* May 2005; 54(2): 284-8. PMID 15837411
180. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed August 17, 2022.
181. Schutz F, Lautenschlager C, Lorenz K, et al. Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis. *Eur Thyroid J.* Jan 2018; 7(1): 13-20. PMID 29594049
182. Haslerud T, Brauckhoff K, Reisaeter L, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. *Acta Radiol.* Oct 2016; 57(10): 1193-200. PMID 26163534
183. Pace L, Klain M, Salvatore B, et al. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. *Clin Nucl Med.* Feb 2015; 40(2): 111-5. PMID 25546215
184. Cheng X, Bao L, Xu Z, et al. F-FDG-PET and F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. *J Med Imaging Radiat Oncol.* Apr 2012; 56(2): 136-42. PMID 22498184
185. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2.2022.

- https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed August 18, 2022.
186. Burglin SA, Hess S, Hoiland-Carlsen PF, et al. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. *Medicine (Baltimore)*. Apr 2017; 96(16): e6713. PMID 28422888
 187. Woo S, Becker AS, Do RKG, et al. Impact of 18 F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. *Eur J Cancer*. Dec 2021; 159: 60-77. PMID 34742159
 188. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Occult Primary. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed August 8, 2022.
 189. Centers for Medicare & Medicaid Services (CMS). Pub 100-03 National Coverage Determination (NCD) for Positron Emission TOMOGRAPHY (FDG) for Oncologic Conditions (220.6.17); <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=331&ncdver=4&NCAId=232&TAId=22&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=tomography&KeywordLookUp=Title&KeywordSearchType=And&bc=gAAAACAAA AAA&>. Accessed July 22, 2022.